200,000+ products from a single source!
sales@angenechem.com
Home > Pyridines > 131986-45-3
131986-45-3 | Pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-
CAS No: 131986-45-3 Catalog No: AG00100T MDL No:MFCD00867179
Product Description
Catalog Number:
AG00100T
Chemical Name:
Pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-
CAS Number:
131986-45-3
Molecular Formula:
C14H23N3OS
Molecular Weight:
281.4169
MDL Number:
MFCD00867179
IUPAC Name:
3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
InChI:
InChI=1S/C14H23N3OS/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12/h8H,3-7,9-11H2,1-2H3
InChI Key:
JOLJIIDDOBNFHW-UHFFFAOYSA-N
SMILES:
CCCCCCOc1nsnc1C1=CCCN(C1)C
UNII:
9ORI6L73CJ
Properties
Complexity:
298
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
281.156g/mol
Formal Charge:
0
Heavy Atom Count:
19
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
281.418g/mol
Monoisotopic Mass:
281.156g/mol
Rotatable Bond Count:
7
Topological Polar Surface Area:
66.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.3
Literature
| Title | Journal |
|---|---|
| Muscarinic acetylcholine receptor-mediated effects in slices from human epileptogenic cortex. | Neuroscience 20121025 |
| Contribution of both M1 and M4 receptors to muscarinic agonist-mediated attenuation of the cocaine discriminative stimulus in mice. | Psychopharmacology 20120401 |
| Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection. | The Journal of pharmacology and experimental therapeutics 20120401 |
| In vitro pharmacological characterization of RXFP3 allosterism: an example of probe dependency. | PloS one 20120101 |
| Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology. | International journal of molecular sciences 20120101 |
| M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition. | Molecular brain 20120101 |
| Distinct muscarinic acetylcholine receptor subtypes mediate pre- and postsynaptic effects in rat neocortex. | BMC neuroscience 20120101 |
| Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity. | PloS one 20120101 |
| Muscarinic mechanisms in psychotic disorders. | Handbook of experimental pharmacology 20120101 |
| The M1/M4 preferring agonist xanomeline is analgesic in rodent models of chronic inflammatory and neuropathic pain via central site of action. | Pain 20111201 |
| Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice-Possible involvement of muscarinic receptors. | Brain research 20111018 |
| The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia. | The international journal of neuropsychopharmacology 20111001 |
| Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold. | Journal of medicinal chemistry 20110714 |
| Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline. | Biochemical and biophysical research communications 20110701 |
| Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20110420 |
| Impact of species variability and 'probe-dependence' on the detection and in vivo validation of allosteric modulation at the M4 muscarinic acetylcholine receptor. | British journal of pharmacology 20110401 |
| Newer molecules in the treatment of schizophrenia: A clinical update. | Indian journal of pharmacology 20110401 |
| Negative cooperativity in binding of muscarinic receptor agonists and GDP as a measure of agonist efficacy. | British journal of pharmacology 20110301 |
| Subtype differences in pre-coupling of muscarinic acetylcholine receptors. | PloS one 20110101 |
| The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. | Molecular pharmacology 20101001 |
| Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics. | Psychopharmacology 20101001 |
| Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. | Journal of medicinal chemistry 20100909 |
| Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia. | Dialogues in clinical neuroscience 20100901 |
| Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. | Current opinion in investigational drugs (London, England : 2000) 20100701 |
| Structural determinants of allosteric agonism and modulation at the M4 muscarinic acetylcholine receptor: identification of ligand-specific and global activation mechanisms. | The Journal of biological chemistry 20100618 |
| The antipsychotic potential of muscarinic allosteric modulation. | Drug news & perspectives 20100501 |
| A novel derivative of xanomeline improves fear cognition in aged mice. | Neuroscience letters 20100405 |
| Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. | Journal of medicinal chemistry 20100311 |
| Attenuation of cocaine's reinforcing and discriminative stimulus effects via muscarinic M1 acetylcholine receptor stimulation. | The Journal of pharmacology and experimental therapeutics 20100301 |
| Update on the pharmacological treatment of Alzheimer's disease. | Current neuropharmacology 20100301 |
| Prefrontal cortex and reversion of atropine-induced disruption of the degraded contingency effect by antipsychotic agents and N-desmethylclozapine in rats. | The international journal of neuropsychopharmacology 20100201 |
| Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice. | Psychopharmacology 20100201 |
| Confocal Analysis of Cholinergic and Dopaminergic Inputs onto Pyramidal Cells in the Prefrontal Cortex of Rodents. | Frontiers in neuroanatomy 20100101 |
| M1 muscarinic receptor for the development of auditory cortical function. | Molecular brain 20100101 |
| Pharmacological evaluation of the long-term effects of xanomeline on the M(1) muscarinic acetylcholine receptor. | PloS one 20100101 |
| Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I. | Current neuropharmacology 20091201 |
| Immediate and delayed consequences of xanomeline wash-resistant binding at the M3 muscarinic receptor. | Neurochemical research 20090601 |
| Mechanisms of M3 muscarinic receptor regulation by wash-resistant xanomeline binding. | Pharmacology 20090501 |
| Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. | European journal of pharmacology 20090301 |
| Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice. | European journal of pharmacology 20090128 |
| Antipsychotic properties of muscarinic drugs. | The American journal of psychiatry 20090101 |
| Reduction in muscarinic M1-mediated hypercholinergic state and beneficial cognitive effects of muscarinic agonists in schizophrenia. | The American journal of psychiatry 20090101 |
| Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands. | BMC pharmacology 20090101 |
| Divergence of allosteric effects of rapacuronium on binding and function of muscarinic receptors. | BMC pharmacology 20090101 |
| Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. | Journal of neurology, neurosurgery, and psychiatry 20081201 |
| Enhancement of memory function in aged mice by a novel derivative of xanomeline. | Cell research 20081101 |
| Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. | European journal of pharmacology 20081031 |
| Role of the central cholinergic system in the therapeutics of schizophrenia. | Current neuropharmacology 20080901 |
| Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. | The American journal of psychiatry 20080801 |
| A novel derivative of xanomeline improved memory function in aged mice. | Neuroscience bulletin 20080801 |
| Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue. | The Journal of pharmacology and experimental therapeutics 20080601 |
| Muscarinic acetylcholine receptors: new potential therapeutic targets in antinociception and in cancer therapy. | Recent patents on CNS drug discovery 20080601 |
| Docking analyses on human muscarinic receptors: unveiling the subtypes peculiarities in agonists binding. | Bioorganic & medicinal chemistry 20080315 |
| Role of M1 receptor in the locomotion behavior of the African mole-rat (Cryptomys sp). | Journal of integrative neuroscience 20080301 |
| Synthesis and evaluation of xanomeline analogs--probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor. | Bioorganic & medicinal chemistry 20080201 |
| Importance and prospects for design of selective muscarinic agonists. | Physiological research 20080101 |
| Long-term changes in the muscarinic M1 receptor induced by instantaneous formation of wash-resistant xanomeline-receptor complex. | The Journal of pharmacology and experimental therapeutics 20071201 |
| Allosteric modulation of muscarinic acetylcholine receptors. | Current neuropharmacology 20070901 |
| Allosteric modulators of class B G-protein-coupled receptors. | Current neuropharmacology 20070901 |
| Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M(2) and M(4) muscarinic receptors in rat brain. | The Journal of pharmacology and experimental therapeutics 20070701 |
| Effects of muscarinic agonists in the guinea-pig prostate. | Autonomic & autacoid pharmacology 20070401 |
| Evaluation of [18F]fluoroxanomeline {5-{4-[(6-[18F]fluorohexyl)oxy]-1,2,5-thiadiazol-3-yl}-1-methyl-1,2,3,6-tetrahydropyridine} in muscarinic knockout mice. | Nuclear medicine and biology 20070201 |
| Design and synthesis of novel derivatives of the muscarinic agonist tetra(ethylene glycol)(3-methoxy-1,2,5-thiadiazol-4-yl) [3-(1-methyl-1,2,5,6-tetrahydropyrid-3-yl)-1,2,5-thiadiazol-4-yl] ether (CDD-0304): effects of structural modifications on the binding and activity at muscarinic receptor subtypes and chimeras. | Journal of medicinal chemistry 20061214 |
| Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor. | Neuroscience letters 20061213 |
| Differences in kinetics of xanomeline binding and selectivity of activation of G proteins at M(1) and M(2) muscarinic acetylcholine receptors. | Molecular pharmacology 20060801 |
| Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. | Molecular pharmacology 20060801 |
| Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor. | The Journal of pharmacology and experimental therapeutics 20051001 |
| Cholinergic effects on fear conditioning II: nicotinic and muscarinic modulations of atropine-induced disruption of the degraded contingency effect. | Psychopharmacology 20050401 |
| The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? | Psychopharmacology 20050401 |
| Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats. | The Journal of pharmacology and experimental therapeutics 20050301 |
| Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. | Progress in neuro-psychopharmacology & biological psychiatry 20041101 |
| Role of receptor protein and membrane lipids in xanomeline wash-resistant binding to muscarinic M1 receptors. | The Journal of pharmacology and experimental therapeutics 20040101 |
| Synthesis and biological characterization of 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as muscarinic agonists for the treatment of neurological disorders. | Journal of medicinal chemistry 20030925 |
| The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys. | Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20030601 |
| [Selective M1 muscarinic agonists: failure of therapeutic strategy against Alzheimer's disease or inappropriate tactics?]. | Annales pharmaceutiques francaises 20030501 |
| The evaluation of cognitive function in the dementias: methodological and regulatory considerations. | Dialogues in clinical neuroscience 20030301 |
| Role of muscarinic receptors in the activation of the ventral subiculum and the consequences for dopamine release in the nucleus accumbens. | European journal of pharmacology 20030124 |
| Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. | CNS drug reviews 20030101 |
| Allosteric modulation by persistent binding of xanomeline of the interaction of competitive ligands with the M1 muscarinic acetylcholine receptor. | The Journal of pharmacology and experimental therapeutics 20020601 |
| Muscarinic receptors as a target for drugs treating schizophrenia. | Current drug targets. CNS and neurological disorders 20020401 |
| Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. | The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20020101 |
| Cholinergic medication for neuroleptic-induced tardive dyskinesia. | The Cochrane database of systematic reviews 20020101 |
| The utility of muscarinic agonists in the treatment of Alzheimer's disease. | Journal of molecular neuroscience : MN 20020101 |
| Design, synthesis, and biological characterization of bivalent 1-methyl-1,2,5,6-tetrahydropyridyl-1,2,5-thiadiazole derivatives as selective muscarinic agonists. | Journal of medicinal chemistry 20011220 |
| The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. | The Journal of pharmacology and experimental therapeutics 20011101 |
| The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. | Biological psychiatry 20010415 |
| Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. | The Journal of pharmacology and experimental therapeutics 20010301 |
| From 'captive' agonism to insurmountable antagonism: demonstrating the power of analytical pharmacology. | Clinical and experimental pharmacology & physiology 20010301 |
| Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. | British journal of pharmacology 19990401 |
| Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors. | British journal of pharmacology 19981201 |
| On the unique binding and activating properties of xanomeline at the M1 muscarinic acetylcholine receptor. | Molecular pharmacology 19980601 |
| PET study of the M1-agonists [11C]xanomeline and [11C]butylthio-TZTP in monkey and man. | Dementia (Basel, Switzerland) 19960101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.